NCT04550832 - PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 28, 2021

Primary Completion Date

January 4, 2023

Study Completion Date

September 11, 2023

Conditions

Infections and InfestationsPulmonary Tuberculosis

Interventions

DRUG

Delpazolid

Delpazolid is not licensed yet. Current experience in humans upto Phase IIA. Dose according to randomization to dosing arms 2-5.

DRUG

Bedaquiline, Delamanid, Moxifloxacin

These three licensed drugs form the backbone of a new regimen to which delpazolid is added in arms 2-5.

Trial Locations (5)

The Aurum Institute Tembisa Clinical Research Centre, Tembisa

Clinical HIV Research Unit (CHRU) University of the Witwatersrand, Johannesburg

Ifakara Health Institute, Bagamoyo

National Institute for Medical Research (NIMR-MMRC), Mbeya

Ki'bongoto Infectious Disease Hospital (KIDH) Kilimanjaro Clinical Research Institute (KCRI), Moshi